tiprankstipranks
Trending News
More News >
Johnson & Johnson (JNJ)
NYSE:JNJ
US Market
Advertisement

Johnson & Johnson (JNJ) Drug Pipeline

Compare
27,038 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Intralipid, Ici35,868 (Diprivan), Ici35,868 (Diprivan) + Ees0000645/A (Sds)
Sedation To Be Moderate For A Diagnostic Gastrointestinal Endoscopy And Gastrointestinal Endoscopic Polypectomy
Phase III
Completed
Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy
Oct 10, 2013
Golimumab
Spondylitis, Ankylosing
Phase III
Completed
Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)
Oct 13, 2011

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Johnson & Johnson (JNJ) have in its pipeline
      JNJ is currently developing the following drugs: Intralipid, Ici35,868 (Diprivan), Ici35,868 (Diprivan) + Ees0000645/A (Sds), Golimumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis